SOURCE: Biotie Therapies Oyj

September 14, 2009 11:45 ET

Biotie starts clinical study with phosphodiesterase 4 inhibitor ELB353

TURKU, FINLAND--(Marketwire - September 14, 2009) -


BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE September 14, 2009 at 1 p.m.

Biotie starts clinical study with phosphodiesterase 4 inhibitor ELB353

Biotie has started a clinical trial with its phosphodiesterase 4 (PDE4) inhibitor ELB353, having received the prerequisite regulatory and ethical clearances for the clinical trial application.

The study will be conducted within the European Union and will evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeated doses of oral ELB353 in up to 48 healthy volunteers. The study is expected to provide proof of pharmacodynamic activity in humans, corroborate the safety profile and establish dose ranges for further therapeutic studies. Results are expected in the first half of 2010.

ELB353 is a once-daily, oral PDE4 inhibitor with therapeutic potential in chronic inflammatory disorders, particularly in chronic obstructive pulmonary disease (COPD), a serious disorder with major unmet medical need.


Turku, September 14, 2009

Biotie Therapies Corp.


Timo Veromaa
President and CEO


Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

Biotie Therapies Corp.

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to www.biotie.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.


Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • For further information, please contact:

    Antero Kallio
    Chief Medical Officer
    Tel. +358 2 274 8900
    e-mail: Email Contact

    Virve Nurmi
    Investor Relations Manager
    tel. +358 2 274 8911
    e-mail: Email Contact

    www.biotie.com